SCHEMBL23798296

SCHEMBL23798296

CC(C)CCNc1ccc(N)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.41
BACE2 Q9Y5Z0 1/20 0.41
ADRA2B P18089 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
ADRA2A P08913 1/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
NQO2 P16083 5/20 0.33
NQO1 P15559 2/20 0.33
POLB P06746 1/20 0.33
TSHR P16473 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HSD17B10 Q99714 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C8 P10632 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22174845 0.82 ADRA2B (0.35) ADRA2BNQO2
SCHEMBL23797765 0.81 IDO1 (0.39) ADRA2BTDP1NQO2POLBALDH1A1
SCHEMBL23709737 0.80 FERMT2 (0.41) ADRA2BTDP1TSHRHSD17B10ALDH1A1
SCHEMBL18403936 0.79 ADRA2B (0.37) ADRA2BTDP1NQO2TSHRALDH1A1
SCHEMBL13718267 0.77 ADRA2B (0.38) ADRA2BTDP1POLBTSHRALDH1A1
SCHEMBL15384343 0.77 MAPT (0.42) ADRA2BTDP1TSHRL3MBTL1ALDH1A1
SCHEMBL19381161 0.77 ALOX5 (0.41) TDP1NQO2POLBTSHRNPSR1
SCHEMBL9024554 0.77 NCF1 (0.44) ADRA2BNQO2NQO1NPSR1ALDH1A1
SCHEMBL7740540 0.77 HDAC1 (0.41) BACE1BACE2
SCHEMBL9024162 0.77 ADRA2B (0.36) ADRA2BTDP1NQO2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
WO-2021178920-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 THERAPEUTICS, INC. (US) 2021-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691972-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 BACE1 3006/4885BACE2 2066/4885ADRA2B 4207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.